BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Becton, Dickinson and Company (BDX) Licenses Intellectual Property to Ivera Medical Corporation


8/26/2008 6:46:29 AM

SAN DIEGO--(BUSINESS WIRE)--Ivera Medical Corporation, a San Diego (CA) based medical device company, today announced an exclusive license agreement with BD (Becton, Dickinson and Company), a global medical technology company, for the worldwide rights to selected BD-issued and pending patents for an intravenous (I.V.) port protector designed to reduce the potential for healthcare-acquired bloodstream infections.

“This license agreement between our two companies confirms our mutual commitment to assist healthcare providers in their efforts to reduce bloodstream infections. We believe a significant number of these infections are caused by touch or airborne contamination of needleless I.V. ports,” Bob Rogers, Chief Executive Officer of Ivera Medical said, in making the announcement.

Healthcare-acquired bloodstream infections dramatically increase a patient’s hospital length of stay, potential mortality and the overall cost of care, according to a recently released study by the Pennsylvania Health Care Cost Containment Council.

Every year in the United States alone healthcare-acquired bloodstream infections are estimated to cost the healthcare system over $5 billion.

“The licensing agreement between BD and Ivera broadens our existing patent applications and removes potential patent issues so we can move forward with the worldwide marketing and sales of the Curos Port Protector,” Jack Saladow, Ivera Vice President of Marketing and Sales said.

“We are very pleased with this exclusive license from BD, and we are looking forward to the expansion of Ivera Medical’s product offering,” Rogers added.

About Ivera Medical Corporation:

Ivera Medical develops, manufactures and markets innovative, high quality medical devices to improve healthcare providers’ management and control of patient infections.

www.iveramedical.com

Contact:

Ivera Medical Corporation Jack Saladow, Vice President of Marketing and Sales 949-495-7097 jsaladow@iveramedical.com

Source: Ivera Medical Corporation

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES